Literature DB >> 2112501

Understanding the molecular basis of coeliac disease.

M F Kagnoff1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2112501      PMCID： PMC1378560          DOI： 10.1136/gut.31.5.497

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  31 in total

Review 1.  DNA polymorphism of HLA class I and class II regions.

Authors:  D Cohen; P Paul; I Le Gall; A Marcadet; M P Font; O Cohen-Haguenauer; B Sayagh; H Cann; J M Lalouel; J Dausset
Journal:  Immunol Rev       Date:  1985-07       Impact factor: 12.988

2.  Analysis of DR beta and DQ beta chain cDNA clones from a DR7 haplotype.

Authors:  R W Karr; P K Gregersen; F Obata; D Goldberg; J Maccari; C Alber; J Silver
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

3.  A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules.

Authors:  J H Brown; T Jardetzky; M A Saper; B Samraoui; P J Bjorkman; D C Wiley
Journal:  Nature       Date:  1988-04-28       Impact factor: 49.962

4.  Predominance of histocompatibility antigen HL-A8 in patients with gluten-sensitive enteropathy.

Authors:  Z M Falchuk; G N Rogentine; W Strober
Journal:  J Clin Invest       Date:  1972-06       Impact factor: 14.808

5.  Mapping SB in relation to HLA and GLO1 using cells from first-cousin marriage offspring.

Authors:  A Termijtelen; P Meera Khan; S Shaw; J J van Rood
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

6.  Immunogenetic aspects of the relationship between HLA-DR and the MB and MT system.

Authors:  R J Duquesnoy
Journal:  Transplant Proc       Date:  1981-12       Impact factor: 1.066

7.  HLA-DR phenotypes in Spanish coeliac children: their contribution to the understanding of the genetics of the disease.

Authors:  M L Mearin; I Biemond; A S Peña; I Polanco; C Vazquez; G T Schreuder; R R de Vries; J J van Rood
Journal:  Gut       Date:  1983-06       Impact factor: 23.059

8.  An HLA-D region restriction fragment length polymorphism associated with celiac disease.

Authors:  M D Howell; R K Austin; D Kelleher; G T Nepom; M F Kagnoff
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

9.  Possible role for a human adenovirus in the pathogenesis of celiac disease.

Authors:  M F Kagnoff; R K Austin; J J Hubert; J E Bernardin; D D Kasarda
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

Review 10.  Genetic complexity and expression of human class II histocompatibility antigens.

Authors:  A J Korman; J M Boss; T Spies; R Sorrentino; K Okada; J L Strominger
Journal:  Immunol Rev       Date:  1985-07       Impact factor: 10.983
View more
  5 in total

1.  Identification of common epitopes on gliadin, enterocytes, and calreticulin recognised by antigliadin antibodies of patients with coeliac disease.

Authors:  S Krupicková; L Tucková; Z Flegelová; M Michalak; J R Walters; A Whelan; J Harries; J Vencovský; H Tlaskalová-Hogenová
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

2.  Increased levels of circulating ICAM-1, E-selectin, and IL-2 receptors in celiac disease.

Authors:  L Jelínková; L Tucková; D Sánchez; S Krupicková; O Pozler; J Nevoral; R Kotalová; H Tlaskalová-Hogenová
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

3.  Evidence for aberrant regulation of MAP kinase signal transduction pathway in peripheral blood mononuclear cells in patients with active celiac disease.

Authors:  E Broide; E Scapa; O Bloch; M Shapiro; N A Kimchi; G Ben-Yehudah; M J Rapoport
Journal:  Dig Dis Sci       Date:  2008-09-12       Impact factor: 3.199

4.  Extracts of wheat gluten activate complement via the alternative pathway.

Authors:  D J Unsworth; R Würzner; D L Brown; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

5.  Asp57-negative HLA DQ beta chain and DQA1*0501 allele are essential for the onset of DQw2-positive and DQw2-negative coeliac disease.

Authors:  V Mantovani; G R Corazza; M Bragliani; M Frisoni; M G Zaniboni; G Gasbarrini
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.